Expression of FBXL5 was shown to be differentially downregulated in CD34+CD38–CD90+ HSCs from MDS patients with deletion of chromosome 5q relative to those from healthy control subjects26. This evidence concerns the gene FBXL5 and myelodysplastic syndrome.